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Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) mainly
encountered in patients with diffuse disease. Unlike idiopathic interstitial pneumonias (IIP),
SSc associated ILD corresponds to non-specific interstitial pneumonia (NSIP) in most cases,
whereas usual interstitial pneumonia (UIP) is encountered less frequently. This explains the
better prognosis of SSc associated ILD compared to IIP. However, severe restrictive lung disease
represents one of the two main causes of disease-related death in SSc patients.
The treatment of SSc associated ILD is not very well established. Anti-fibrosing treatments
have failed to demonstrate any benefit and cyclophosphamide, which has been used in the
treatment of this condition for about 15 years, has recently been evaluated in two prospective
randomised studies which showed a significant but modest effect on respiratory function. Since
none of the patients included in retrospective or prospective studies were selected on the
basis of progression of ILD, and since only a minority of SSc patients develop severe ILD, further
studies should focus on the subgroup of SSc patients with worsening ILD.
A subgroup of patients with rapidly progressive ILD might benefit from pulsed intravenous
cyclophosphamide combined with prednisone 15 mg daily but this remains to be confirmed.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Systemic sclerosis (SSc) is a connective tissue disease that is
characterized by excessive collagen deposition, autoim-
munity, and extensive vascular damage that involves
multiple organs.1,2Me´decine Interne, Hoˆpital
ues, 75679 Paris Cedex 14,
þ33 1 58 41 14 50.
aphp.fr (L. Mouthon).
0 Elsevier Ltd. All rights reservedSSc mainly occur in females between 45 and 64 years
old.3 The prevalence of SSc is not very well characterized,
estimated in the USA and in Australia between 200 and
260 cas/million inhabitants,3,4 in Asia between 20 and 50/
million inhabitants5 and in Europe between 100 and
200 cas/million inhabitants.6,7
Patients with SSc are classified according to the extent of
skin involvement: limited SSc (lSSc), with no detectable skin
involvement; limited cutaneous SSc (lcSSc)8 with skin involve-
ment essentially limited to the hands and face; and diffuse SSc
(dSSc), with skin involvement proximal to the elbows and
knees.9 In patientswith lcSSc, visceral involvement is rare, and.
S60 L. Mouthon et al.the prognosis is good, with the exception of the 8%e12% of
patients in whom pulmonary arterial hypertension, interstitial
lung disease and/or bowel involvement eventually occur.10
Patients with dSSc experience visceral involvement, which is
responsible for reduced life expectancy.11 In addition to
diminishing life expectancy, SSc is responsible for skin, tendon,
joint, and vessel damage, which leads to disability, handicap,
and worsening of quality of life.12
Interstitial lung disease associated with SSc
ILD is more frequently associated with diffuse forms of SSc.
Since SSc associated ILD may develop in the absence of
dyspnoea, high resolution computed tomography (HRCT)
must be performed systematically in SSc patients, together
with pulmonary function tests (PFT). ILD occurs in 16e100%
of SSc patients.11,13 However, it can be encountered in
approximately 75% of the patients when it is systematically
looked at. Forty-five percent to fifty-five percent of
patients with ILD deteriorate their PFTs early (during the
first 3 years) in the course of their illness, even when they
are asymptomatic.11,13 Among these patients, not all have
progressive disease, and only 16% of them develop severe
restrictive lung disease (FVC < 55%).11
As reported recently in a series of 80 SSc patients who
underwent surgical lung biopsies, SSc associated ILD usually
correspond to non-specific interstitial pneumonia
(NSIP)14,15 according to the new classification criteria for
interstitial pneumonias.16 Thus, NSIP is much more preva-
lent (76%) than usual interstitial pneumonia (UIP) (11%) in
this setting.15 In some case, however, lung biopsy does not
allow to differentiate between these two forms and
evidences unclassified end-stage lung fibrosis.
Although the prognosis differs between the two histo-
logical types in idiopathic interstitial pneumonias, NSIP
having a longer course and a relatively lesser decline of
pulmonary function and a better response to therapy than
UIP,14,16 this finding is probably not true in scleroderma. In
the large series of Bouros et al. including 80 patients, the
result of pathological examination of surgical lung biopsies
did not influence the prognosis, contrary to DLCO at
inclusion, worsening of DLCO at three years and hyper-
eosinophilia upon bronchoalveolar lavage (BAL) which were
found associated with increased mortality.15
As in the case of idiopathic ILD, SSc patients with ILD can
be managed on the basis of PFTs.17 In addition, high reso-
lution computed tomography (HRCT) represent a reliable
non-invasive approach for the detection and monitoring the
pulmonary involvement in SSc patients.13,18e20
The treatment of ILD associated with SSc should be
based on current concepts of disease pathogenesis, which
remains incompletely understood.1,2 Collagen accumula-
tion results from abnormal interactions among endothelial
cells (EC), mononuclear cells (lymphocytes and monocytes)
and fibroblasts leading to the production of fibrosis-
inducing cytokines, in a setting of vascular hyperreactivity
and tissue hypoxia. The pathogenesis consists of a combi-
nation of inflammatory, destructive and fibrosing lesions.
The pulmonary fibrotic lesions are associated with an
increased incidence of a class II MHC DR3/DR52a and/or the
presence of anti-topoisomerase I (Scl-70) antibodies in the
serum. Inflammatory cells (neutrophils, eosinophils,macrophages, lymphocytes) and other inflammation medi-
ators are present in BAL fluid of SSc patients with ILD,
reflecting ongoing inflammation in the lungs.21,22 Thus,
based on evidence suggesting that inflammation precedes
fibrosis in SSc, corticosteroids and immunosuppressive
therapy have been proposed in SSc associated ILD. Histor-
ically, as in the case of idiopathic pulmonary fibrosis,
corticosteroids represented the treatment of choice of SSc
associated ILD. However, to date, there is no documented
efficacy of this treatment, whereas there have been recent
concerns of an increase risk of developing scleroderma
renal crisis in patients receiving corticosteroids.23
Prognosis
The prognosis of SSc-ILD is better than that of idiopathic
pulmonary fibrosis.24 Black and Asian ethnicity,24,25 male
sex, heart involvement and early diffuse SSc are more often
associated with a severe form of ILD.26 However, these
results have not been confirmed in other studies.27
The two main points allowing to define the prognosis of
SSc-ILD are immediately severe PID, based on clinical
(dyspnoea, crackles), functional (TLCO and/or FVC < 70%)
and high resolution computed tomography (HRCT) (exten-
sive lesions with dominant ground glass); or rapidly
progressive ILD (defined by a loss of 10% of FVC or 15% of
TLCO) during the last 12 months.25 For most of the authors,
bronchoalveolar lavage does not influence therapeutic
management. However, in the study conducted by Bouros
et al. a proportion of eosinophils over 5% in BAL repre-
sented a bad prognosis criterion.15
Histological type of PID is of no prognosis value. In the
same study, no correlation has been found between histo-
logical type and survival, as opposed to TLCO and
a proportion of eosinophils over 5% in BAL.15
Thus, it is mandatory to follow the progression of ILD by
performing pulmonary function tests every six months,
eventually more frequently in case of clinical worsening in
the absence of another explanation such as PAH or super-
infection. Thus, rapid progressions, corresponding to
subacute exacerbations, may occur during the course of
SSc-ILD and their early detection might improve thera-
peutic management. Survival of patients with SSc-ILD is
variable. At five years, it is probably around 90%, estimated
to be at 85% in 1994 altogether.13 In diffuse forms of the
disease, all causes of death taken together, survival at 9
years of patients with ILD is 38%.11 Overall, 12% of patients
with SSc-ILD develop severe chronic respiratory
insufficiency.25
Finally, it seems that patients with SSc-ILD might be
exposed to an increased risk of developing lung cancer,
more often an adenocarcinoma or a bronchioloalveolar
carcinoma, although this point remains controversial.28,29
Treatment of interstitial lung disease
associated with SSc
It is important to mention that symptomatic treatments
such as oxygenotherapy, rehabilitation and treatment of
gastroeoesophagal reflux are very important in the
management of SSc-ILD.
Treatment of scleroderma associated pulmonary fibrosis S61Anti-fibrosing agents
Various therapeutic strategies have been proposed to treat
ILD in SSc patients.30 Several anti-fibrosing therapies have
been evaluated in the treatment of SSc-ILD. However, all of
them failed to demonstrate beneficial effect in high vs low
dose or placebo-controlled trials.31e34
D-penicillamin (DP), or 2eaminoe3emercaptoevaline,
had been recommended since the early 1970 for the
treatment of SSc, with improvement of skin involvement.
Only one retrospective study evidenced a survival
improvement in patients with pulmonary fibrosis.35
However, the use of DP is limited due to the large number
of adverse events such as proteinuria, gastrointestinal tract
involvement, cytopenia, induction of autoimmune diseases
and constrictive bronchiolitis36 and a recent prospective
double-blind study provided evidence that DP doses usually
prescribed (750e1000 mg/j) were not more efficient and
yielded to more frequent adverse events than low doses
(125 mg every other day during two years).33 These data
challenge the possible efficacy of DP in the treatment of
SSc patients.
Gamma interferon (IFN-g) is the strongest inhibitor of
collagen synthesis by fibroblasts.37 Since 1989, IFN-g has
been proposed in the treatment of SSc in six open stud-
ies.38e43 Four of these studies reported an efficacy on skin
involvement as measured by Rodnan skin score,39e41,43 one
reported an improvement of skin score, oesophageal and
joint symptoms,38 whereas in another study no significant
benefit was observed.42 In the only prospective randomised
study available, skin involvement was improved under IFN-g
therapy, whereas no difference was evidence in the case of
ILD.43 Only one prospective randomised trial evaluated IFN-
a against placebo in SSc patients. No clinical improvement
was noted and worsening of ILD was documented in
patients receiving IFN-a.32
Corticosteroids
On the basis of the evidence suggesting that inflammation
precedes fibrosis in SSc, corticosteroids and immunosup-
pressive therapy have been proposed in SSc associated ILD.
Historically, corticosteroids represented the treatment of
choice of SSc-ILD. However, to date the efficacy of corti-
costeroids has not been documented in SSc-ILD. Since
a number of studies reported an increased risk of devel-
oping scleroderma renal crisis in patients receiving high
dose corticosteroids,23,44,45 we recommend to use cortico-
steroids at low dose (less than 15 mg/day) only in patients
with severe worsening ILD.46
Immunosuppressive agents
Immunosuppressive agents were tested in the late 1980s in
the treatment of SSc patients and 5-FU and chlorambucyl
also failed to demonstrate benefit in placebo-controlled
trials.47,48
Cyclophosphamide
Since more than 15 years, cyclophosphamide (CYC) is used
in the treatment of SSc patients with ILD. CYC is a cytotoxicimmunosuppressive agent that suppresses lymphokine
production and modulates lymphocyte function by alkylat-
ing various cellular constituents and depressing the
inflammatory response via normalization of neutrophilia
and healing of vascular endothelial cells.49 In 1993, Silver
and colleagues were the first to report that SSc patient with
ILD and evidence of lung inflammation upon bron-
chioalveolar lavage (BAL) who were treated with oral CYC
appeared to have a stable lung function at follow-up. In
that study, 93% of patients had improved or stabilized their
lung function at 6 months. The improvement was main-
tained in the group of patients who completed 24 months of
CYC treatment (FVC 63.6  4.3%, p < 0.001).50 Since then,
the beneficial effect of oral51e58 or intravenous
(IV)54,56,59e66 CYC in the treatment of SSc-related ILD was
documented in retrospective studies, sometimes in associ-
ation with low doses of corticosteroids,50,60,63,67 with
improvement of PFTs and/or chest computed tomography
at one year (Table 1).
In 2000, White and colleagues analysed 103 SSc patients
including 69 with evidence of alveolitis, as identified by
lung biopsy or BAL. Thirty nine of these patients received
CYC whereas 30 did not. These two groups were compared
with a control group of 34 SSc patients who had no evidence
of alveolitis and did not receive CYC. SSc patients with
alveolitis who received CYC were more likely than those
who did not to have a good outcome in FVC (72% vs 23%,
ORZ 2.5) and in DLCO (49% vs 27%, ORZ 2.5). The change
in percentage of predicted FVC and DLCO differed for
treated and untreated patients with alveolitis (pZ 0.05 for
FVC; pZ 0.02 for DLCO). The rate of change did not differ
in treated patients and patients without alveolitis
(p > 0.2), and the survival rate was greater among patients
with alveolitis who received CYC than among untreated
patients (p Z 0.01).53
Long-term oral CYC therapy may cause significant
treatment-related toxicity, as a consequence of the high
cumulative dose of CYC. Thus, the risk of myelosup-
pression, infertility, and infection could be diminished by
using IV CYC. There are now data available in the literature
that compare the efficacy of IV and oral CYC utilized alone
ore in combination with corticosteroids. Davas et al.
reported on 16 SSc patients with alveolitis who received
CYC. Eight of them were treated with monthly CYC pulses
(750 mg/m2) for 12 months, and the 8 others received oral
cyclophosphamide (2e2.5 mg/kg per day) during the same
period. In both groups, there was evidence for an efficacy
of CYC with a regression of ground glass aspects after 12
months, whereas reticular lesions remained stable.60
Unfortunately, it is no possible to compare pulse with oral
CYC therapy because of the different pattern seen on HRCT
between the two groups.
Two recent prospective, randomised, placebo-
controlled studies have helped to clarify the effect of
CYC in the treatment of SSc associated ILD. A multicenter,
double-blind, randomised, placebo-controlled North
American trial, the Scleroderma Lung Study,68 evaluated
the effect of oral CYC on lung function and health-related
symptoms in 158 SSc patients with evidence of active
alveolitis. The primary outcome was FVC. The mean abso-
lute difference in FVC at 12 months between treatment and
placebo group was 2.53%, favouring CYC (p < 0.03). The
Table 1 Clinical studies performed with cyclophosphamide in the treatment of interstitial lung disease associated with systemic sclerosis.
Author, Year Treatment Study design N Inclusion criteria Follow-up
(months)
Primary end-
point
Outcome
Sabnani I Oral imatinib (200 mg/day)
and intravenous CYC
(500 mg every 3 weeks)
Prospective
observational
study
5 Advanced SSc-ILD
(demonstrated
abnormalities on HRCT).
6 to 12 FVC, DLCO Only the patient with mild restrictive lung disease
showed improvement in pulmonary function.
Simeon-Aznar,
200879
IV CYC (500e750 mg/m2 per
month) during 6e24
months.
Prospective
observational
study
10 Chest HRCT compatible
with SSc-related ILD
and/or FVC  80% of the
predicted value on PFT.
At least
36
FVC, DLCO,
HRCT
The median values of FVC and DLCO as well as
ground-glass pattern on HRCT did not change
significantly after 6, 12 and 24 months of therapy.
Only one patient suffered FVC deterioration
greater than 10%.
Be´rezne´,
200880
IV CYC (600 mg/m2 per
month)  6 followed by oral
AZA for 18 months
Retrospective
uncontrolled
27 ILD and worsening of FVC
and/or TLC of more than
10% and/or DLCO of
more than 15% during the
previous year.
24 FVC, DLCO Twenty-three completed 2-year followup, 3 died,
and one dropped out. Six (22.2%) had improved, 8
(29.6.%) were stable, and 13 (48.2%) had
worsened. Evolution of the slope of FVC (in % per
year) varied from 15.5 prior to treatment to þ3
(p Z 0.004) at 6 months and to þ1 (p < 5  10
(5)) at 24 months.
Holyes, 200670 IV CYC (600 mg/m2 per
month)  6 þ 20 mg oral
prednisolone on alternate
day followed by AZA
(2.5 mg/kg/d) vs placebo.
Prospective,
randomised,
double-blind,
placebo-
controlled
45 SSc associated
pulmonary fibrosis upon
HRCT or lung biopsy
Median disease duration
was 2.75 years in active
treatment group and 5.5
years in placebo group
12 FVC and DLCO Trend toward statistical significance in the active
treatment group vs placebo group. Improvement
of FVC of 2.4% in active treatment group and
decline of 3% in placebo group (p Z 0.08).
- No difference in DLCO between the two groups
(p Z 0.64)
- No significant change in secondary end-points:
HRCT score (p Z 0.39), dyspnoea scores
(p Z 0.23)
Tashkin, 200668 Oral CYC (2 mg/kg/d) vs
placebo  12 mo.
Prospective,
randomised,
double-blind,
placebo-
controlled.
158 - SSc of less than 7 years
of evolution
- Active alveolitis
assessed by BAL or HRCT
or 45% < FVC < 85%
Median disease duration
was 3.2 years
24 FVC Primary and secondary outcome at 12 months
- Difference between two group in change in FVC:
2.53% (p Z 0.03) favouring CYC group
- Difference between two group in TLCO: 4.09%
favouring CYC group (p Z 0.026)
- No difference for DLCO (p Z 0.43) and DLCO/VA
(p Z 0.92)
Yiannopoulos,
200767
IV CYC (750e1000 mg/m2/
mo) þ 1 g IV MP  12 mo and
bimonthly for 12e18
additional months
Prospective
uncontrolled
13 HRCT abnormalities
Median disease duration
was 1.2 years
48 FVC and DLCO - DLCO: at 24 mo. 66% were stabilized or improved
(NS). This result was not maintained at 48 mo.
- FVC: at 24 mo and 48 mo. 66.6% were stabilized
or improved (NS)
- HRCT: mean HRCT score 11.8  6.1 pretreatment
vs 12.7 uncontrolled 6.9 (NS)
- No correlation between the evolution of HRCT
score and PFT
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Ostojic, 200666 IV CYC (500 mg/m2/
mo)  6 mo.
Prospective
uncontrolled
19 DLCO and/or DLCO/
VA < 70%
Median disease duration
was 5.7 years
7 FVC, DLCO and
DLCO/VA
- FVC change: 86.6% vs 89.2% (NS)
- Significant improvement of DLCO (pZ 0.04) and
DLCO/VA (p Z 0.008)
Beretta, 200758 Oral CYC (2 mg/kg/d) and
low-dose prednisone
(25 mg/d for 3 months and
then tapered to
5 mg)  12 mo.
Prospective
uncontrolled
33 Active alveolitis (ground
glass appearance upon
HRCT) and a recent
deterioration in lung
function (decline >7% in
FVC and/or DLCO in last
6 mo.)
Median disease duration
was 5.6 years
12 FVC and DLCO DLCO remained stable at 6 mo and significantly
increased at 12 mo (p < 0.001)
FVC stable at 6 and 12 mo (NS).
Kowal-
bielecka,
200665
IV CYC (1000 mg/m2/
mo)  6 and oral prednisone
(<10 mg/d)
Retrospective
uncontrolled
21 HRCT abnormalities and
decrease >10% of FVC or
neutrophilic alveolitis
(NA)
Median disease duration
was 5 years
6 BAL Improvement of BAL granulocyte count of patients
with NA before treatment (p < 0.05)
Correlation of NA before treatment with
improvement of FVC (p < 0.05)
Airo, 200456 IV CYC 750 mg þ 125 mg MP
(6 pulses)
Retrospective
uncontrolled
16 Active alveolitis upon
BAL and/or HRCT.
Median disease duration
was 2.4 years
11 FVC and DLCO Moderate improvement in FVC (þ2.7%, p Z 0.08)
and in DLCO ((þ2.2%, p Z 0.08)
Griffiths,
200263
IV CYC 15 mg/kg and IV MP
(10 mg/kg) at 3e4 week
intervals  6 mo.
Prospective
uncontrolled
14 HRCT abnormality
(ground glass)
DLCO < 75%, TLC < 80%
Median duration of ILD
was 1 year
6 HRCT, FVC and
DLCO
13% HRCT improvement (p Z 0.04)
No significant change in FVC or DLCO but a trend
toward greater improvement in DLCO in patients
with early ILD
Giacomelli,
200262
IV CYC (1000 mg/m2/
mo)  6 and oral prednisone
(25 mg/d 1 mo, 5 mg/d  5)
Prospective
uncontrolled
23 Active alveolitis on BAL
with altered PFT or
recent deterioration of
FVC
6 HRCT, FVC and
DLCO, BAL
FVC, DLCO, HRCT and BAL (NS)
Pakas, 200161 IV CYC (500 then 750 mg/
m2/mo)  6 then bimonthly
for another 6 mo.
In the low dose steroid
group: no improvement at 6
and 12 mo.and low-dose
prednisolone (<10 mg/d)or
High-dose prednisolone
(1 mg/kg/d) for 4 weeks;
then taper gradually
Prospective
uncontrolled
28 FVC < 70%
Median disease duration
in the low-dose
prednisone group was 4.8
years vs 3 years in high-
dose prednisone group
12 HRCT, FVC and
DLCO
In the low dose steroid group: no improvement at
6 and 12 mo.
In the high dose steroid group:
Improvement of HRCT score (p Z 0.003)
Significant increase in FVC (pZ <0.001) and DLCO
(p Z 0.029)
(continued on next page)
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Table 1 (continued)
Author, Year Treatment Study design N Inclusion criteria Follow-up
(months)
Primary end-
point
Outcome
White, 200053 Oral CYC 2 mg/kg/
d  12 mo or IV CYC
(800e1400 mg/
mo  6e9 mo.) or no
treatment
Retrospective
uncontrolled
103 SSc with ILD who
experienced BAL or lung
biopsy
- Active alveolitis on BAL
or lung biopsy who
received CYC (n Z 39)
- Active alveolitis on BAL
or lung biopsy who did
not receive CYC (nZ 30)
- Absence of active
alveolitis on BAL or lung
biopsy (n Z 34)
103 FVC and DLCO - 72% of patients with alveolitis who received CYC
stabilized or improved FVC (OR Z 2.5); 49% of
patients with lveolitis who received CYC tabilized
or improved DLCO (OR Z 1.5).
- Patients with alveolitis who did not received CYC
experienced further decrease in FVC (7.1%) and
in DLCO (9.6%).
- Changes in FVC and DLCO differed between
treated and untreated patients with alveolitis
(p Z 0.005 for FVC; p Z 0.02 for DLCO)
- Survival improved between patients with
alveolitis who received CYC (89%) and those who
did not (71%) (p Z 0.01).
Davas, 199960 Oral CYC (2e2.5 mg/kg/
d) þ oral prednisolone
(10 mg/d)  12 mo.
or
IV CYC (750 mg/m2/
mo.)  12 mo.
Prospective
uncontrolled
16 ILD assessed by HRCT
Median disease duration
was 5 years
12 HRCT, FVC and
DLCO
Oral CYC group:
- Improvement of HRCT score at 12 mo.
(p Z 0.043)
- Improvement of DLCO at 12 mo. (p Z 0.036) IV
CYC group
- Improvement of HRCT score at 12 mo (pZ 0.012)
- Improvement of FVC (p Z 0.025) and DLCO
(p Z 0.012) at 12 mo.
- Correlation between DLCO and change in the
extent of disease on HRCT (rZ 0.85, pZ 0.007)
Varai, 199881 IV CYC 1 g/mo  12 mo. Prospective
uncontrolled
5 FVC <80% or ILD
confirmed by HRCT
Median disease duration
was 2.1 years
12 FVC and DLCO,
HRCT, BAL,
Dyspnoea score
- FVC increased by 7% as compared to baseline
(NS)
- DLCO: 12%decrease (NS)
- BAL: decrease in cell number but not in the
percentage of neutrophils
- Dyspnea score: decreased by 48%
- No change in HRCT
Akesson, 199482 Oral CYC (2e2.5 mg/kg/
d)  12 mo. and prednisone
30 mg/d
Prospective,
uncontrolled
18 Abnormal findings on PFT
(mean 74% of FVC and
52% of DLCO) and/or
evidence of ILD on HRCT
Median disease duration
was 2.5 years
12. FVC and DLCO - Improvement of FVC in 78% patients (74%e80%
(p < 0.01))
- No improvement of DLCO
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Treatment of scleroderma associated pulmonary fibrosis S65mean absolute difference in TLC was also significant
(4.09%), favouring CYC. On the other hand, there was no
difference for DLCO and DLCO/VA. In addition, CYC
improved dyspnoea with a significant difference between
the two groups in the transitional dyspnea index (p < 0.001)
and Health assessment questionnaire (HAQ) disability
index, skin score, and vitality and health transition scales
of the Medical Outcomes Study (MOS) 36-Item Short-Form
Health Survey (SF-36) (p < 0.05).68 Unfortunately, at two
years, overall differences between treatment groups were
less, especially for pulmonary function tests (evolution rate
of FVC was 2.0% vs 2.3% in the placebo group) and no
significant beneficial effect could be demonstrated.69
A second trial, Fibrosing Alveolitis in Scleroderma Trial
(FAST), included 45 patients with SSc-related ILD who were
randomised to receive prednisolone (20 mg/d) and 6 CYC
infusions (0.6 g/m2 monthly) or placebo. Estimation of the
relative treatment effect (active treatment vs placebo)
adjusted for baseline FVC and treatment centre revealed
a mean improvement of 4.19% of FVC; with a trend toward
statistical significance (pZ 0.08). No improvement in DLCO
or secondary outcome measures was identified.70 The
sample size of this study was limited, which may in part
explain the failure to achieve statistical significance. Thus,
none of these trials demonstrated a beneficial effect of CYC
as compared to placebo.68e70
In a prospective randomised study, 30 patients with SSc
received oral CYC (2 mg/kg/day for 1 year and then 1 mg/
kg/day) and 30 patients received oral AZA (2.5 mg/kg/day
for 1 year then maintained at 2 mg/kg/day) for 18 months.
All the patients received prednisone more than 15 mg/day,
progressively reduced and then stopped after 6 months. At
the end of the study the Rodnan cutaneous score, the
incidence of Raynaud’s syndrome and the ESR were
improved in the group treated with CYC whereas the FVC
and DLCO did not change in the group treated with CYC but
deteriorated in the group treated with AZA.57
Taken together these results do not favour the use of CYC
in SSc associated ILD. However, none of the patients included
in retrospective or prospective studies were selected on the
basis of progression of ILD with the exception of study of
Silver in 1993, where 9/14 patients had a significant decline
in FVC in 3e24 months before study entry. This is probably
one of the reasons that would explain the difficulties
encountered to demonstrate a clinically relevant benefit of
CYC in patients with SSc-related ILD. Thus, as reported by
Steen et al. only a small proportion of patients with SSc-
related ILD develop severe worsening ILD.25
Although ILD represent one of the two main causes of
mortality in SSc patients, we think that we should focus on
patients with worsening ILD and maintain follow-up
patients with stable PFT without initiating immunosup-
pressive therapy. We recently reported a series of SSc
patients treated with intravenous CYC followed by oral
maintenance immunosuppressive therapy for worsening
ILD. The treatment was well tolerated and was associated
with stable or improved PFT in 70% and 51.8% of SSc
patients at 6 months and 2 years, respectively.71
Thus, the current approach is to evaluate lung involve-
ment in the early years of disease, in order to assess the
patient’s risk of progressive pulmonary fibrosis. We could
propose to select SSc patients with ILD on the basis of
S66 L. Mouthon et al.significant worsening of PFT during the last 6 or 12 months
and treat them with CYC. We will start at the beginning of
2010 a prospective randomised trial comparing one year
treat with intravenous CYC and low-dose prednisone and
low-dose prednisone alone in SSc patients with worsening
ILD. A trial comparing oral CYC and mycophenolate mofetil
(MMF) in SSc patients with ILD is ongoing in the USA.
Mycophenolate mofetil
MMF is more and more prescribed in patients with SSc. Nih-
tyanova and colleagues treated 109 SSc patients with or
without ILD with MMF and compared them to 63 control SSc
subjects receiving other immunosuppressive drugs. 12% of
patients experiencedadverse reactions (gastrointestinal (GI)
tract disturbances, infections). MMFwas discontinued due to
disease stabilization in 9%, side effects in 8% and no effect on
the disease activity in 14% of the patients. The authors
reported significantly lower frequency of clinically signifi-
cant pulmonary fibrosis in the MMF-treated cohort
(pZ 0.037) and significantly better 5-yr survival fromdisease
onset and from commencement of treatment (pZ 0.027 and
pZ 0.012, respectively). No significant difference was evi-
denced between the two groups for modified Rodnan skin
score or FVC.72 In another study performed in 13 patients
with SSc-ILDwho presented significant decrease in FVC in the
12 months prior to MMF treatment, significant improvement
in FVC was noted after 12 months.73
Lung transplantation
In patients in whom the disease progresses despite CYC
therapy, single lung transplantation may be considered if
there is no other visceral involvement or digital ulceration.
Schachna and colleagues compared the results obtained in
29 SSc patients with end-stage ILD or PAH, 70 patients with
idiopathic pulmonary fibrosis (IPF) and 38 patients with
idiopathic pulmonary arterial hypertension (IPAH) who
underwent lung transplantation. During the 2 years of
follow up, 11 patients with SSc (38%), 23 with IPF (33%), and
14 with IPAH (37%) died. Cumulative survival at 2 years was
comparable (64%) in the three groups.74
Therapeutic perspectives
There is a need for new treatments in SSc-ILD. A number of
drugs have been reported to exert beneficial effect in
patients with SSc-ILD such as bucillamin. Anti-TGFb mono-
clonal antibodies failed to show beneficial effect in
a prospective dose ranging study.75 However, the antibody
was not very active and other anti-TGFb monoclonal anti-
bodies are currently being developed. Anti-connective
tissue growth factor monoclonal antibodies might be
promising in SSc. Bosentan, an antagonist of endothelin 1
receptors has been tested in a prospective randomised trial
(BUILD 2) in SSc-ILD and failed to show beneficial effect.
Pirfenidone76 and N-acetyl cysteine77 showed beneficial
effect in patients with IPF and should be evaluated in SSc-
ILD. Finally, imatinib, dazatinib, other tyrosine kinase
inhibitors are promising and evaluated in a number of
ongoing studies.Conclusion
The ILD of SSc is most often slowly progressive. However, in
a small proportion of cases it may progress rapidly to
respiratory failure11 and today it constitutes one of the two
main causes of death in SSc.78 Routine monitoring of PFT is
a key element in the detection of rapid progression of the
disease and should allow the initiation of immunosuppres-
sant treatment with the minimum delay. Two prospective
randomised trials failed to demonstrate a clinically rele-
vant beneficial effect of CYC as compared to placebo in the
treatment of SSc associated ILD. Since none of the patients
included in retrospective or prospective studies were
selected on the basis of progression of ILD, further studies
are needed to evaluate whether CYC therapy might exert
a beneficial effect in patients with worsening ILD.
Conflict of interest statement
LM is a consultant for Pfizer, Actelion France and Lilly. DV is
a consultant for Intermune, Actelion, Boehtringer and
Centocor.Acknowledgements
We thank Daniel Dusser for helpful suggestions. This work
was supported by the Association des scle´rodermiques de
France. Alice Be´rezne´, Loı¨c Guillevin and Luc Mouthon are
members of the Groupe Franc¸ais de Recherche sur la
Scle´rodermie (GFRS).
References
1. Servettaz A, Agard C, Tamby M, Guilpain P, Guillevin L,
Mouthon L. Physiopathologie de la scle´rodermie syste´mique:
e´tat des lieux sur une affection aux multiples facettes. Presse
Med 2006;35:1903e15.
2. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights
into the pathogenesis of systemic sclerosis. Autoimmun Rev
2003;2(3):152e7.
3. Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW,
Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and
disease characteristics of systemic sclerosis in a large US
population. Arthritis Rheum 2003;48(8):2246e55.
4. Roberts-Thomson PJ, Walker JG. Scleroderma: it has been
a long hard journey. Intern Med J 2006;36(8):519e23.
5. Tamaki T, Mori S, Takehara K. Epidemiological study of patients
with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283
(6):366e71.
6. Magnant J, Diot E. Systemic sclerosis: epidemiology and envi-
ronmental factors. Presse Med 2006;35(12 Pt 2):1894e901.
7. Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M,
Guillevin L. Prevalence of systemic sclerosis in a French multi-
ethnic county. Rheumatology (Oxford) 2004;43(9):1129e37.
8. LeRoy EC, Medsger Jr TA. Criteria for the classification of early
systemic sclerosis. J Rheumatol 2001;28(7):1573e6.
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T,
Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classi-
fication, subsets and pathogenesis. J Rheumatol 1988;15(2):
202e5.
Treatment of scleroderma associated pulmonary fibrosis S6710. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E,
Sibilia J, et al. Early detection of pulmonary arterial hyper-
tension in systemic sclerosis: a French nationwide prospective
multicenter study. Arthritis Rheum 2005;52(12):3792e800.
11. Steen VD, Medsger Jr TA. Severe organ involvement in systemic
sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43
(11):2437e44.
12. Casale R, Buonocore M, Matucci-Cerinic M. Systemic sclerosis
(scleroderma): an integrated challenge in rehabilitation. Arch
Phys Med Rehabil 1997;78(7):767e73.
13. Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-
Taylor AJ, et al. Fibrosing alveolitis associated with systemic
sclerosis has a better prognosis than lone cryptogenetic fibrosing
alveolitis. Am J Respir Crit Care Med 1994;149:1583e90.
14. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, et al.
Interstitial lung diseases associated with collagen vascular
diseases: radiologic and histopathologic findings. Radio-
graphics 2002;22(Spec No):S151eS165.
15. Bouros D,Wells AU, Nicholson AG, Colby TV, Polychronopoulos V,
Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis
in patients with systemic sclerosis and their relationship to
outcome. Am J Respir Crit Care Med 2002;165(12):1581e6.
16. American Thoracic Society/European Respiratory Society
International Multidisciplinary Consensus Classification of the
Idiopathic Interstitial Pneumonias. This joint statement of the
American Thoracic Society (ATS), and the European Respira-
tory Society (ERS) was adopted by the ATS board of directors,
June 2001 and by the ERS Executive Committee, June 2001. Am
J Respir Crit Care Med 2002;165(2):277e304.
17. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma
lung disease. N Engl J Med 2006;354(25):2707e9.
18. Remy-Jardin M, Remy J, Cortet B, Mauri F, Delcambre B. Lung
changes in rheumatoid arthritis: CT findings. Radiology 1994;
193(2):375e82.
19. Diot E, Boissinot E, Asquier E, Guilmot JL, Lemarie E, Valat C,
et al. Relationship between abnormalities on high-resolution
CT and pulmonary function in systemic sclerosis. Chest 1998;
114(6):1623e9.
20. Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I,
Hachulla E, Lambert M, et al. High resolution computed
tomography in fibrosing alveolitis associated with systemic
sclerosis. J Rheumatol 2006;33(9):1789e801.
21. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F,
Konig G, et al. Bronchoalveolar lavage for evaluation and
management of scleroderma disease of the lung. Am J Respir
Crit Care Med 1996;154(2 Pt 1):400e6.
22. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM.
Cytokineconcentrations inbronchoalveolar lavagefluidofpatients
with systemic sclerosis. Arthritis Rheum 1997;40(4):743e51.
23. Steen VD, Medsger TA. Case-control study of corticosteroids
and other drugs that either precipitate or protect from the
development of scleroderma renal crisis. Arthritis Rheum
1998;41(9):1613e9.
24. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger Jr TA,
Wright TM. Influence of ethnic background on clinical and sero-
logic features in patients with systemic sclerosis and anti-DNA
topoisomerase I antibody. Arthritis Rheum 1999;42(3):465e74.
25. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive
lung disease in systemic sclerosis. Arthritis Rheum 1994;37(9):
1283e9.
26. Jacobsen S, Halberg P, Ullman S, Hoier-Madsen M, Petersen J,
Mortensen J, et al. A longitudinal study of pulmonary function
in Danish patients with systemic sclerosis. Clin Rheumatol
1997;16(4):384e90.
27. Peters-Golden M, Wise RA, Schneider P, Hichberg M, Stevens MB,
Wigley F. Chemical and demographic predictors of loss of
pulmonary function in systemic sclerosis. Medicine 1984;63:
221e31.28. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM.
Incidence of lung cancer in systemic sclerosis. J Rheumatol
1985;12(6):1136e9.
29. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of
malignancy in scleroderma: a population-based cohort study.
Arthritis Rheum 2005;52(8):2415e24.
30. Mouthon L, Berezne A, Poiraudeau S, Guillevin L. Therapeutic
management of systemic sclerosis. Presse Med 2006;35(12 Pt
2):1975e82.
31. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B,
Jabkowski J, MacHeiner W, et al. Interferon-gamma in the
treatment of systemic sclerosis: a randomized controlled
multicentre trial. Br J Dermatol 1998;139(4):639e48.
32. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H,
Newman J, et al. Interferon-alpha does not improve outcome
at one year in patients with diffuse cutaneous scleroderma:
results of a randomized, double-blind, placebo-controlled
trial. Arthritis Rheum 1999;42(2):299e305.
33. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F,
et al. High-dose versus low-dose D-penicillamine in early diffuse
systemic sclerosis: analysis of a two-year, double-blind,
randomized, controlled clinical trial. Arthritis Rheum 1999;42
(6):1194e203.
34. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW,
Mayes MD, et al. Recombinant human relaxin in the treatment
of scleroderma. A randomized, double-blind, placebo-
controlled trial. Ann Intern Med 2000;132(11):871e9.
35. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA. The
effect of D-penicillamine on pulmonary findings in systemic
sclerosis. Arthritis Rheum 1985;28(8):882e8.
36. Steen VD, Blair S, Medsger TA. The toxicity of D-penicillamine
in systemic sclerosis. Ann Intern Med 1986;104(5):699e705.
37. Granstein RD, Flotte TJ, Amento EP. Interferons and collagen
production. J Invest Dermatol 1990;95:75s.
38. Kahan A, Amor B, Menkes CJ, Strauch G. Recombinant inter-
feron gamma in the treatment of systemic sclerosis. Am J Med
1989;87:273e7.
39. Freundlich B, Jimenez SA, Steen VD, Medsger TA, Szkolnicki M,
Jaffe HS. Treatment of systemic sclerosis with recombinant
interferon-gamma. A phase I/II clinical trial. Arthritis Rheum
1992;35(10):1134e42.
40. Hein R, Behr J, Hundgen M, Hunzelmann N, Meurer M, Braun-
Falco O, et al. Treatment of systemic sclerosis with gamma-
interferon. Br J Dermatol 1992;126(5):496e501.
41. Bletry O, Laraki R, Cabane J, Frances C, Piette JC, Soubrier M,
et al. Long-term results of the treatment of diffuse systemic
scleroderma with interferon-gamma. Rev Med Interne 1993;14
(10):978.
42. Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, Galaris D,
Papiris SA, Moutsopoulos HM. Safety and efficacy of recombi-
nant gamma interferon in the treatment of systemic sclerosis.
Ann Rheum Dis 1996;55(10):761e8.
43. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA,
Simon LS. A multicenter trial of recombinant human interferon
gamma in patients with systemic sclerosis: effects on cuta-
neous fibrosis and interleukin 2 receptor levels. J Rheumatol
1996;23:654e8.
44. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK,
Hurwitz EL, et al. Predictors and outcomes of scleroderma
renal crisis: the high-dose versus low-dose D-penicillamine in
early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46
(11):2983e9.
45. Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C,
Mehrenberger M, et al. Mortality and risk factors of sclero-
derma renal crisis: a French retrospective study of 50 patients.
Ann Rheum Dis 2008;67(1):110e6.
46. Berezne A, Valeyre D, Ranque B, Guillevin L, Mouthon L.
Interstitial lung disease associated with systemic sclerosis:
S68 L. Mouthon et al.what is the evidence for efficacy of cyclophosphamide? Ann N Y
Acad Sci 2007;1110:271e84.
47. Casas JA, Saway PA, Villarreal I, Nolte C, Menajovsky BL,
Escudero EE, et al. 5-fluorouracil in the treatment of sclero-
derma: a randomised, double blind, placebo controlled inter-
national collaborative study. Ann Rheum Dis 1990;49(11):
926e8.
48. Clements P, Lachenbruch P, Furst D, Paulus H. The course of
skin involvement in systemic sclerosis over three years in a trial
of chlorambucil versus placebo. Arthritis Rheum 1993;36(11):
1575e9.
49. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA,
et al. The efficacy of oral cyclophosphamide plus prednisolone
in early diffuse systemic sclerosis. Clin Rheumatol 2003;22
(4e5):289e94.
50. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH,
Strange C. Cyclophosphamide and low-dose prednisone
therapy in patients with systemic sclerosis (scleroderma) with
interstitial lung disease. J Rheumatol 1993;20:838e44.
51. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved
pulmonary function in systemic sclerosis after treatment with
cyclophosphamide. Arthritis Rheum 1994;37(5):729e35.
52. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA. Therapy
for severe interstitial lung disease in systemic sclerosis. A
retrospective study. Arthritis Rheum 1994;37(9):1290e6.
53. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophos-
phamide is associated with pulmonary function and survival
benefit in patients with scleroderma and alveolitis. Ann Intern
Med 2000;132(12):947e54.
54. D’Angelo S, Cuomo G, Paone C, Colutta E, La Montagna G,
Valentini G. Low-dose intravenous cyclophosphamide in
systemic sclerosis: a preliminary safety study. Clin Rheumatol
2003;22(6):393e6.
55. Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M.
Pulse cyclophosphamide decreases sympathetic postganglionic
activity, controls alveolitis, and normalizes vascular tone
dysfunction (Raynaud’s phenomenon) in a case of early
systemic sclerosis. Arthritis Rheum 2004;51(4):665e9.
56. Airo P, Danieli E, Parrinello G, Antonioli CM, Cavazzana I,
Toniati P, et al. Intravenous cyclophosphamide therapy for
systemic sclerosis. A single-center experience and review of
the literature with pooled analysis of lung function test results.
Clin Exp Rheumatol 2004;22(5):573e8.
57. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A random-
ized unblinded trial of cyclophosphamide versus azathioprine
in the treatment of systemic sclerosis. Clin Rheumatol 2006;25
(2):205e12.
58. Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L,
et al. Oral cyclophosphamide improves pulmonary function in
scleroderma patients with fibrosing alveolitis: experience in
one centre. Clin Rheumatol 2007;26(2):168e72.
59. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophos-
phamide in the treatment of interstitial lung disease due to
collagenvasculardiseases.Arthritis Rheum1998;41(7):1215e20.
60. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D,
Dantis PC. Intravenous cyclophosphamide pulse therapy for the
treatment of lung disease associated with scleroderma. Clin
Rheumatol 1999;18(6):455e61.
61. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM,
Vlachoyiannopoulos PG. Cyclophosphamide with low or high
dose prednisolone for systemic sclerosis lung disease. J Rheu-
matol 2002;29(2):298e304.
62. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P,
Conforti ML, et al. Cyclophosphamide pulse regimen in the
treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;
29(4):731e6.
63. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P.
Systemic sclerosis and interstitial lung disease: a pilot studyusing pulse intravenous methylprednisolone and cyclophospha-
mide to assess the effect on high resolution computed tomog-
raphy scan and lung function. J Rheumatol 2002;29(11):2371e8.
64. Mittal G, Udwadia Z, Joshi VR. Cyclophosphamide pulse
regimen in the treatment of alveolitis in systemic sclerosis. J
Rheumatol 2003;30(5):1121e2 [author reply 1122].
65. Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A,
Siergiejko Z, Sierakowska M, et al. Cyclophosphamide reduces
neutrophilic alveolitis in patients with scleroderma lung
disease: a retrospective analysis of serial bronchoalveolar
lavage investigations. Ann Rheum Dis 2005;64(9):1343e6.
66. Ostojic P, Damjanov N. Improvement of lung function in
patients with systemic sclerosis after 6 months cyclophospha-
mide pulse therapy. Clin Rheumatol; 2006:1e3.
67. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G,
Kalliolias G, Liossis SN, et al. Combination of intravenous pul-
ses of cyclophosphamide and methylprednizolone in patients
with systemic sclerosis and interstitial lung disease. Rheumatol
Int 2007;27(4):357e61.
68. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD,
Furst DE, et al. Cyclophosphamide versus placebo in sclero-
derma lung disease. N Engl J Med 2006;354(25):2655e66.
69. Clements PJ, Furst D, Silver R, Tashkin D, Roth M, Goldin J,
et al. Outcomes at 24-months are better for patients who
received one-year of cyclophosphamide (CYC) therapy for SSc
alveolitis than in those who received one-year of placebo (PBO)
in the scleroderma lung study; 2006.
70. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS,
et al. A multicenter, prospective, randomized, double-blind,
placebo-controlled trial of corticosteroids and intravenous
cyclophosphamide followed by oral azathioprine for the
treatment of pulmonary fibrosis in scleroderma. Arthritis
Rheum 2006;54(12):3962e70.
71. Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y,
Launay D, et al. Therapeutic strategy combining intravenous
cyclophosphamide followed by oral azathioprine to treat
worsening interstitial lung disease associated with systemic
sclerosis: a retrospective multicenter open-label study.
J Rheumatol 2008;35(6):1064e72.
72. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycopheno-
late mofetil in diffuse cutaneous systemic sclerosisea retro-
spective analysis. Rheumatology (Oxford) 2007;46(3):442e5.
73. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate
mofetil on pulmonary function in scleroderma-associated
interstitial lung disease. Chest 2008;133(2):455e60.
74. Schachna L, Medsger Jr TA, Dauber JH,Wigley FM, Braunstein NA,
White B, et al. Lung transplantation in scleroderma compared
with idiopathic pulmonary fibrosis and idiopathic pulmonary
arterial hypertension. Arthritis Rheum 2006;54(12):3954e61.
75. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM,
et al. Recombinant human anti-transforming growth factor
beta1 antibody therapy in systemic sclerosis: a multicenter,
randomized, placebo-controlled phase I/II trial of CAT-192.
Arthritis Rheum 2007;56(1):323e33.
76. Azuma A. Shared mechanisms of lung injury and subsequent
fibrosis: role of surfactant proteins in the pathogenesis of
interstitial pneumonia in HermanskyePudlak Syndrome. Intern
Med 2005;44(6):529e30.
77. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R,
Jansen HM, et al. High-dose acetylcysteine in idiopathic
pulmonary fibrosis. N Engl J Med 2005;353(21):2229e42.
78. Steen VD, Medsger TA. Changes in causes of death in systemic
sclerosis, 1972e2002. Ann Rheum Dis 2007;66(7):940e4.
79. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva OCA,
Solans-Laque R, Palliza E, et al. Intravenous cyclophosphamide
pulse therapy in the treatment of systemic sclerosis-related
interstitial lung disease: a long term study. Open Respir Med
J 2008;2:39e45.
Treatment of scleroderma associated pulmonary fibrosis S6980. Berezne´ A, Valeyre D, Le Guern V, Brauner M, Mahr A,
Constans J, et al. Therapeutic strategy combining intrave-
nous cyclophosphamide (CYC) and azathioprine to treat
severe systemic sclerosis (SSc): a prospective open-label
study including 52 patients. Arthr Rheum 2005;52
[Abstract 352].81. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study
of intermittent intravenous cyclophosphamide for the treat-
ment of systemic sclerosis associated lung disease. J Rheu-
matol 1998;25(7):1325e9.
82. Akesson A. Cyclophosphamide therapy for scleroderma. Curr
Opin Rheumatol 1998;10(6):579e83.
